Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Conjugating drugs to therapeutic antibodies is a promising strategy to increase their therapeutic efficacy. Shen et al. show that the local chemical environment of the conjugation site influences the in vivo stability and efficacy of the modified antibodies.
Liver toxicity is one of the most common reasons for abandoning new drugs in development or withdrawing approved drugs from the market. Patel et al. show that in mice drug-induced liver injury can be limited by small-molecule inhibitor of the gap-junctional protein connexin 32.